Literature DB >> 10552979

Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients.

I Adamsson1, C E Nord, P Lundquist, S Sjöstedt, C Edlund.   

Abstract

Fourteen patients with Helicobacter pylori infection were treated with 20 mg omeprazole, 1 g amoxycillin and 400 mg metronidazole bd for 7 days (OAM), and 16 patients were treated with 20 mg omeprazole, 250 mg clarithromycin and 400 mg metronidazole bd for 7 days (OCM). Saliva, gastric biopsies and faecal samples were collected before, during (day 7) and 4 weeks after treatment in order to analyse alterations of the normal microflora and to determine antimicrobial susceptibility. Both treatment regimens resulted in marked quantitative and qualitative alterations. A selection of resistant streptococcal strains were noticed in both treatment groups, most apparent in the OCM group where a shift from susceptible to resistant strains was recorded. In the OAM group, six patients had overgrowth of resistant enterobacteriaceae during treatment compared with none in the OCM group, in the gastric microflora. The MICs for Enterococcus spp. and Enterobacteriaceae in faeces increased significantly during treatment in both groups. Nine patients in the OAM group became intestinally colonized by yeasts during treatment. The total anaerobic microflora was strongly suppressed in both treatment groups, although most pronounced in the OCM group, where the frequency of clarithromycin-resistant bacteroides strains increased from 2 to 76% during treatment, and remained at 59% 4 weeks post-treatment. Even if the treatment outcome was better in the OCM group (100%) than in the OAM group (71%), the amoxycillin-based treatment might be preferable from an ecological point of view, since the qualitative alterations in terms of emergence and persistence of resistant strains seemed to be most pronounced in the clarithromycin-treated group.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552979     DOI: 10.1093/jac/44.5.629

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  34 in total

1.  Treatment of Helicobacter pylori infection. Development of resistance to antibiotics used must be avoided.

Authors:  G G Rao; J O'Donohue; C S Mahankali Rao; H Fidler
Journal:  BMJ       Date:  2000-06-03

2.  Management of Helicobacter pylori infection. Treatment of ulcers can be improved and over-reliance on proton pump inhibitors reduced.

Authors:  Ian L P Beales; Helena K Parsons; David S Sanders; Martyn J Carter; Alan J Lobo; Trevor Watts
Journal:  BMJ       Date:  2002-03-09

3.  Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

Authors:  Yi-Chia Lee; Jyh-Ming Liou; Ming-Shiang Wu; Chun-Ying Wu; Jaw-Town Lin
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

4.  Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern.

Authors:  Kyland P Holmes; John C Fang; Brian R Jackson
Journal:  BMC Health Serv Res       Date:  2010-12-21       Impact factor: 2.655

Review 5.  What is the Relevance of Gastric Microbiota Beyond H. pylori?

Authors:  Kerstin Schütte; Peter Malfertheiner; Christian Schulz
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

6.  Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.

Authors:  Hedvig E Jakobsson; Cecilia Jernberg; Anders F Andersson; Maria Sjölund-Karlsson; Janet K Jansson; Lars Engstrand
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

Review 7.  The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis.

Authors:  Alexander Sheh; James G Fox
Journal:  Gut Microbes       Date:  2013-08-19

8.  Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

Authors:  Chung-Wei Lee; Barry Rickman; Arlin B Rogers; Zhongming Ge; Timothy C Wang; James G Fox
Journal:  Cancer Res       Date:  2008-04-25       Impact factor: 12.701

9.  Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

Authors:  Chung-Wei Lee; Barry Rickman; Arlin B Rogers; Sureshkumar Muthupalani; Shigeo Takaishi; Peiying Yang; Timothy C Wang; James G Fox
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

Review 10.  Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed?

Authors:  Jin Young Park; David Forman; E Robert Greenberg; Rolando Herrero
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.